Phaseline

Companies › Summit Therapeutics

Summit Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ivonescimab Dose 1
TIGIT inhibitor
TIGIT, CTLA4Phase 3Non-Small Cell Lung Cancer; Metastatic Urothelial CarcinomaApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06767514Ivonescimab Dose 1Phase 3Non-Small Cell Lung CancerOncologyApr 2028
NCT05899608Ivonescimab Dose 1Phase 3Non-Small Cell Lung CancerOncologyDec 2028
NCT07815665Ivonescimab Dose 1Phase 2Metastatic Urothelial CarcinomaOncologyOct 2030
NCT07815665Ivonescimab Dose 1Phase 2Metastatic Urothelial CarcinomaOncologyOct 2030

From the company's SEC filings

Cash and short-term investments of $630m on 2026-09-30; operating cash outflow about $568m a year; runway about 13 months at that burn, to Nov 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TIGIT (1) CTLA4 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Xencor Innovent Biopharmaceutical Technology (Hangzhou) Roche D3 Bio (Wuxi) Gilead Sciences Shanghai Huaota Biopharmaceutical Suzhou Suncadia Biopharmaceuticals Arcus Biosciences

Companies built like this

SynOx Therapeutics NingBo Junyan Hongshi Biosciences Taizhou Hanzhong biomedical InSightec Agenus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.